Evidence map›Paper›PMID 42699265›Full record

ReviewFrontiers in immunology2026

Advances in CAR-T therapy for central nervous system lymphoma.

Xiumei Feng, Jing Yang, Xiaofei Xu, Wen Kai, Yanxin Huang, Shanshan Zhang, Lin Su, Leisheng Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiumei FengDepartment of Hematology, The Fourth People's Hospital of Jinan Affiliated to Shandong Second Medical University, Jinan, China.
Jing YangLaboratory of Precision Medicine, The Fourth People's Hospital of Jinan Affiliated to Shandong Second Medical University, Jinan, China.
Xiaofei XuDepartment of Neurosurgery, The Fourth People's Hospital of Jinan Affiliated to Shandong Second Medical University, Jinan, China.
Wen KaiRehabilitation & Health Care Ward, The Fourth People's Hospital of Jinan Affiliated to Shandong Second Medical University, Jinan, China.
Yanxin HuangDepartment of Hematology, The Fourth People's Hospital of Jinan Affiliated to Shandong Second Medical University, Jinan, China.
Shanshan ZhangShandong Provincial Key Medical and Health Laboratory of Blood Ecology and Biointelligence, Jinan Key Laboratory of Medical Cell Bioengineering, Science and Technology Innovation Center, The Fourth People's Hospital of Jinan Affiliated to Shandong Second Medical University, Jinan, China.
Lin SuDepartment of Respiratory Medicine and Critical Care, The Fourth People's Hospital of Jinan, Affiliated to Shandong Second Medical University, Jinan, China.
Leisheng ZhangShandong Provincial Key Medical and Health Laboratory of Blood Ecology and Biointelligence, Jinan Key Laboratory of Medical Cell Bioengineering, Science and Technology Innovation Center, The Fourth People's Hospital of Jinan Affiliated to Shandong Second Medical University, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of relapsed/refractory B-cell lymphomas, yet its initial use in central nervous system lymphoma has been hampered by safety concerns and limited efficacy. Current data are derived from small, heterogeneous trials, with unresolved questions regarding neurotoxicity mitigation, optimal treatment timing, long-term response durability, and predictive biomarkers, precluding widespread clinical implementation. This narrative review systematically integrates peer-reviewed clinical trials, real-world retrospective datasets and preclinical mechanistic investigations to summarize the efficacy and safety profile of CAR-T in patients with PCNSL and SCNSL.

Indexed as

Central Nervous System NeoplasmsImmunotherapy, AdoptiveLymphomaReceptors, Chimeric AntigenAnimalsHumansReceptors, Antigen, T-CellTreatment OutcomeReceptors, Antigen, T-CellReceptors, Chimeric AntigenCAR-T therapyCNS lymphomaneurotoxicity syndromesprimary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)

Identifiers

PMID42699265
PMCPMC13542976

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.